The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
The firm is focused on helping pharma characterize response and resistance to their drugs, with the hope of getting a companion diagnostic approval.
The firm expects a first readout from an investigator-initiated trial of an in vivo CAR T-cell therapy in the second half of this year.
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...
The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.
The FDA previously declined to approve UX111 citing CMC-related observations, but the firm is hopeful the agency will approve its new regulatory application.
The partners will focus on treating Swiss patients with very rare diseases and then use the framework developed to establish similar pathways throughout Europe.
NEW YORK – The European Commission has approved a high-dose regimen of Biogen's Spinraza (nusinersen), an antisense oligonucleotide for 5q spinal muscular atrophy (SMA).
The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.
The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer ...
The firm's share price fell after a presentation at the conference revealed lower-than-expected Elevidys sales.
The company highlighted multiple myeloma and CAR T therapies as growth drivers and announced two new US manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback